Medindia

X

NeoGenomics to Present at the Wall Street Analyst Forum on November 28, 2007

Monday, November 26, 2007 General News J E 4
Advertisement
FT. MYERS, Fla., Nov. 26 NeoGenomics, Inc.(OTC Bulletin Board: NGNM) announced today that President and Chief ScientificOfficer, Bob Gasparini, will present at the Wall Street Analyst Forum's 18thAnnual Conference being held from November 27-28, 2007 at the Princeton Clubin New York City. The conference will showcase smallcap public life sciencescompanies. NeoGenomics is scheduled to present on Wednesday, November 28th at10:30 AM. A webcast of the presentation can be accessed athttp://www.wsw.com/webcast/wsaf5/ngnm. A PowerPoint presentation and a linkto the webcast can also be accessed through the investor relations section ofthe NeoGenomics website at http://www.neogenomics.org at the time of theconference. The webcast will be available for three months.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratorythat specializes in cancer genetics diagnostic testing, the fastest growingsegment of the laboratory industry. The company's testing services includecytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry,morphology studies, anatomic pathology and molecular genetic testing.Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN,Irvine, CA and Fort Myers and services the needs of pathologists, oncologists,urologists, hospitals and other reference laboratories throughout the UnitedStates. For additional information about NeoGenomics, visithttp://www.neogenomics.org.

Interested parties can also access additional investor relations materialfrom the American Microcap Institute athttp://www.americanmicrocapinstitute.com/ngnm/ or from Hawk Associates athttp://www.hawkassociates.com. An investment profile about NeoGenomics may befound at http://www.hawkassociates.com/ngnmprofile.aspx.

SOURCE NeoGenomics, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Food and Drug Law Institute Sponsors Colloquium on...
S
E-Rad Solutions Selects Compressus' Enterprise Sys...